| Study | Country Study period Study design |
Data source | Exposure definition | Non-exposure definition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
|---|---|---|---|---|---|---|---|---|
|
Barataud-Reilhac A (Control exposed to IFN or GLA) 2019 |
France 2014 - 2016 retrospective cohort (claims database) |
French national health insurance information system (SNIIRAM) | Pregnant MS women exposed to teriflunomide, i.e woman had taken it during pregnancy or did not follow the appropriate recommendations (accelerated disposal procedure) after treatment stop. |
exposed to other treatment, sick
Pregnant MS women exposed to interferons or glatiramer acetate (IFN-GA) during pregnancy. |
during pregnancy (anytime or not specified) | 47 / 673 | ||
| The French national health insurance database (DCIR) containing all individualized and anonymous health care claims reimbursed by French National Health Insurance. | ||||||||
|
Barataud-Reilhac A (Control unexposed, sick) 2019 |
France 2014 - 2016 retrospective cohort (claims database) |
French national health insurance information system (SNIIRAM) | Pregnant women exposed to teriflunomide, i.e woman had taken it during pregnancy or did not follow the appropriate recommendations (accelerated disposal procedure) after treatment stop. |
unexposed, sick
Pregnant women with no treatment (NOTT). |
during pregnancy (anytime or not specified) | 47 / 1538 | ||
| The French national health insurance database (DCIR) containing all individualized and anonymous health care claims reimbursed by French National Health Insurance. | ||||||||
| Study | Country Study period Study design |
Data source | Case | Control | Exposition | Exposition period | Sample size (exposed/unexposed) Or (case / control) |
Remarks | Risk of bias |
|---|
Risk of bias: : NA; : low; : moderate; : serious; : critical; : unclear;
-
About
-
Master protocol
-
Browse exposition
-
RSS
-
Made with in Lyon
-
Contact us
-
Privacy policy
-
